Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To End on December 4th

Septerna’s (NASDAQ:SEPN) quiet period is set to expire on Wednesday, December 4th. Septerna had issued 16,000,000 shares in its public offering on October 25th. The total size of the offering was $288,000,000 based on an initial share price of $18.00. During the company’s quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analysts Forecast Growth

SEPN has been the subject of a number of research analyst reports. Cantor Fitzgerald began coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. TD Cowen initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective on the stock.

Septerna Trading Up 2.1 %

Shares of NASDAQ:SEPN opened at $25.29 on Friday. Septerna has a twelve month low of $18.62 and a twelve month high of $26.34.

Insider Transactions at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was acquired at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the acquisition, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.